ClinicalTrials.gg
CompletedNCT02658357Updated Feb 19, 2020Results posted

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

A Phase 2 interventional study of Risperidone Implant in Schizophrenia and Schizo-affective Disorder, sponsored by Braeburn Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by Braeburn Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2015, registered Jan 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
87th of 123
66 · median 100
Started
2015
with 5 others
Phase 2
4 of 127
none open now
Registered
99th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 87th largest by enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2015, is one of 4 in phase 2, and was the 99th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants.

Read the detailed description

The study will be a 6-month, open-label, study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants.

Subjects who are diagnosed with schizophrenia or schizoaffective disorder according to DSM-V and are stable on a daily 4 mg oral dose of Risperidone for at least 8 weeks will be recruited into the study.

Subjects stable on a 4 mg oral dose of Risperidone will be implanted with two or three, 300 mg, Risperidone Implants. All implants will be placed in the inner aspect of the upper arm. Plasma concentrations of Risperidone and the active moiety will be measured prior to placement of the Risperidone Implants, throughout the implantation period, and after re-converting to oral Risperidone following the removal of the Risperidone Implants.

03

Conditions studied

  • Schizophrenia
  • Schizo-affective Disorder
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject (and/or a subject's authorized legal representative) has provided written
  2. Patient meets the following criteria:

    • Outpatient status
    • PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20% change from screening, the patients cannot participate in the study.
    • A score of ≤ 3 on the following PANSS items:

      • Conceptual disorganization
      • Suspiciousness
      • Hallucinatory behavior
      • Unusual thought content
  3. Subject is male or female between 18 to 60 years of age
  4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to , 5th edition (DSM-V) criteria

Exclusion criteria

Exclusion Criteria:

  1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator
  2. Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide
  3. Has a current or recent (within 12 months) diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening.
  4. Have impaired hepatic (/AST >1.5 times higher than the ) or renal function (\<50 mL/min)
  5. Previously defined to Risperidone
  6. History of neuromalignant syndrome (NMS)
  7. Electroconvulsive therapy within 6 months of admission
  8. Requires current use of agents that are strong inhibitors and inducers of cytochrome P450 2D6
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    600 mg

    Two, 300 mg Risperidone Implants

    Drug: Risperidone Implant

  • Experimental
    900 mg

    Three, 300 mg Risperidone Implants

    Drug: Risperidone Implant

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone

    Time frame: 6 months

  2. Cmax for Active Moiety, 9-hydroxy-risperidone and Risperidone

    Time frame: 6 months

Secondary outcomes

  1. Safety and Efficacy of a Risperidone Implant as Assessed by the Positive and Negative Syndrome Scale (PANSS)

    Time frame: 12 months

07

Results

Posted Feb 19, 2020
Limitations and caveats
The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study

Participant flow

Participant flow — Overall Study
Milestone600 mg900 mg
Started00
Completed00
Not completed00

Outcome measures

PrimaryArea Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone
Time frame:
6 months

No measurements were reported for this outcome.

PrimaryCmax for Active Moiety, 9-hydroxy-risperidone and Risperidone
Time frame:
6 months

No measurements were reported for this outcome.

SecondarySafety and Efficacy of a Risperidone Implant as Assessed by the Positive and Negative Syndrome Scale (PANSS)
Time frame:
12 months

No measurements were reported for this outcome.

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
600 mg———
900 mg———

Baseline characteristics

The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

Age, Categorical
Age, Categorical600 mg900 mgTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Age, Continuous
Age, Continuous600 mg900 mgTotal
Sex: Female, Male
Sex: Female, Male600 mg900 mgTotal
Female———
Male———
Race (NIH/OMB)
Race (NIH/OMB)600 mg900 mgTotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of Enrollment(participants)600 mg900 mgTotal
08

Study locations

1 site
  • Segal Institute for Clinical Research 1201 North 37th Avenue
    Hollywood, Florida 33021, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Aug 2017, 22 months.

Results were first posted in Feb 2020, 2 years 6 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 22 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2016
First posted
Jan 18, 2016
StartActual
Oct 2015
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Feb 19, 2020
Last update
Feb 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02658357
Lead sponsor
Braeburn Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 18, 2016
Start date
Oct 2015
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Feb 19, 2020
Last update
Feb 19, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion